2026-01-15 - Analysis Report
**Merck & Co Inc (MRK) Company Overview**
A multinational pharmaceutical company.

**Return Rate Comparison**
- Review Stock (MRK): 25.01%
- Comparison Stock (VOO): 93.94%
- Divergence: cumulative return on the last day of the data is -68.90

**Cumulative Return Comparison**
- MRK: 25.01%
- VOO: 93.94%

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7 | 186.3B |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7 | 221.7B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7 | 199.4B |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6 | 195.8B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5 | 283.5B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3 | 278.6B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3 | 254.2B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3 | 268.9B |

**Recent Stock Price Fluctuations**
- Close: $108.26
- Last-Market: $110.75
- 5-day SMA: $109.51
- 20-day SMA: $105.54
- 60-day SMA: $97.24
- Current price is above the 5-day SMA.

**RSI, PPO Index Indicators, Delta_Previous_Relative_Divergence, and Expected_Return**
- Market Risk Indicator (MRI): 0.70
- RSI: 64.07 (neutral)
- PPO: -0.05
- Expected Return: -30.60%

**Recent News & Significant Events**
- FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential - Yahoo Finance
- Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case - Chartmill
- Is Merck Stockâ€™s Run Legitimate? - Forbes
- Kera Capital Partners Inc. Buys 9,382 Shares of Merck & Co., Inc. $MRK - MarketBeat
- Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s - Reuters
- 3 Dividend Stocks to Hold for the Next 10 Years - The Motley Fool

**Analyst Opinions**
- Analyst Consensus: Buy
- Mean: 1.90
- Opinions: 27
- Target Price (avg/high/low): $113.33 / $135.00 / $83.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | $2.32 | $17.28B |
| 2025-08-05 | $1.76 | $15.81B |
| 2025-05-02 | $2.01 | $15.53B |
| 2024-11-06 | $1.25 | $16.66B |

**Financial Information - Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

**Financial Information - Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Comprehensive Analysis (Summary of previous items)**

Based on the provided data, Merck & Co Inc (MRK) has a lower cumulative return rate of 25.01% compared to the S&P 500 with a return rate of 93.94%. Recent news and significant events suggest that the company is focusing on new growth opportunities and has blockbuster potential. The recent stock price fluctuations show that the current price is above the 5-day SMA, indicating a slight uptrend. The RSI indicator is neutral at 64.07, and the PPO indicator is negative at -0.05. The expected return is -30.60%, indicating a potential decline in value over the long term. Analyst opinions are generally positive, with a consensus of "Buy" and a target price of $113.33. The financial data shows consistent revenue and profit margins, with a slight decline in ROE over the quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.